Hello again Jkuchta,
The results of my research are as follows:
Singulair sales
($ in millions)
2005 2,975.6
2004 2,622.0
2003 2,009.4
Source:
Merck 2005 Annual Report - Financial Section
http://www.merck.com/finance/annualreport/ar2005/pdf/Merck_2005_Financial_Review.pdf
?Singulair , Merck?s once-a-day leukotriene receptor antagonist
continued its strong performance in 2002 as an asthma controller.
Total 2002 sales of Singulair were $1.5 billion, an increase of 19%
over 2001. Excluding the estimated impact of wholesaler buying
patterns, the year-on-year growth of Singulair approximated 26%.
Worldwide sales of Singulair in 2003 are expected to approximate $2.0
billion to $2.3 billion. Singulair is the No. 1 prescribed asthma
controller among allergists and pediatricians in the United States,
and since its launch in 1998, more than 40 million prescriptions of
Singulair have been dispensed to patients.?
($ in millions)
2002 1,505.6
2001 1,268.8
Hoover?s
http://www.hoovers.com/free/co/secdoc.xhtml?ID=10986&ipage=2215670
?Total 2002 sales of Singulair were $1.5 billion, an increase of 19% over 2001.?
Merck Annual Report 2002
http://www.merck.com/finance/annualreport/ar2002/merck_financial_section.pdf
($ in millions)
2000 $860 million
?Singulair, Merck?s once-a-day leukotriene antagonist, is one of the
top-selling asthma controllers worldwide. Sales in 2000 were $860
million, up 72 percent compared to 1999.?
http://www.anrpt2000.com/access1.htm
?Singulair grew sales 107% in 2001 to $860 million, but the
opportunity is forthcoming as Merck strives for broader usage of the
asthma drug.?
http://www.fool.com/portfolios/rulemaker/2001/rulemaker010821.htm
*************************************************
Value of the U.S. over-the-counter cold and cough preparations market
for 2003, 2005 and 2005
Year Cough and cold preparations
2005 2.6 billion
?Cough and cold preparations gain 9.0%, driven by a strong cold and flu season?
Source: (Bar chart on page 7)
Kline & Company
Nonprescription Drugs USA 2005
http://www.klinegroup.com/reports/brochures/cia6d/brochure.pdf
Year Cough and cold preparations
2004 2.3 billion
Source: (Bar chart on page 7)
Kline & Company
Nonprescription Drugs USA 2004
http://www.klinegroup.com/reports/brochures/cia6c/brochure.pdf
Year Cough and cold preparations
2003 2.25 billion
Source: (Bar chart on page 6)
Kline & Company
Nonprescription Drugs USA 2003
http://www.klinegroup.com/reports/brochures/cia6b/brochure
*************************************************
Value of the market for cough, cold, and allergy remedies in the United States 2001
According to a Kline & Company market research report published
September 2002, the market for the cough, cold, and allergy remedies
in the United States was worth about $2.8 billion in 2001.
?The cough, cold, and allergy remedies market continues to grow
modestly while facing increasing competition from prescription
products.?
?Allergy, asthma, and sinus products are predicted to grow by only
1.3% annually, while cough and cold preparations will grow 3% annually
through 2006.?
?Consumers are purchasing more private-label products as a result of
the recession in the last quarter of 2001. Lowerpriced private-label
products will increase their market share but will see diminishing
dollar growth.?
The U.S Cough, Cold, and Allergy Remedies Market 2001
Mindbranch: Market Research Reports
http://www.mindbranch.com/listing/product/R379-0102.html
*************************************************
Total value of the U.S. prescription antihistamine market 2001
Market share for Loratidine Allegra and Zyrtec for the same year.
(Allegra is non-sedating)
?Total retail community pharmacy sales of loratadine were $2.25 billion in 2001?
?The total prescription antihistamine market was approximately $4.69
billion for that year, with loratadine accounting for nearly half of
the total.?
?Two other second-generation antihistamines, Allegra and Zyrtec,
accounted for 24.8% and 20.8% of the market, respectively.?
Managed Pharmaceutical Report, March 2003
http://www.rxsolutions.com/c/pbi/pbi_view.asp?docid=322
*************************************************
Estimated value of the US prescription antihistamine market 2002
Retail value of the total US OTC cough, cold and allergy products sector 2002
?Prescription-only antihistamines include Claritin by Schering-Plough,
Alavert by Wyeth, Allegra by Aventis, and Zyrtec by Pfizer. The first
is the best-selling of the three, with all three worth over US$3bn in
prescription sales in 2001.?
"The US prescription antihistamine market is estimated at US$3.8
billion, only US$380 million less than the US$4.2 billion retail value
of the total US OTC cough, cold and allergy products sector.
Euromonitor
OTC Claritin set to have major impact on US market
Date published: 16 Jan 2003
http://www.euromonitor.com/OTC_Claritin_set_to_have_major_impact_on_US_market
*************************************************
Below you will find the additional material I was able to locate today.
US antihistamine market share (September 2002)
See pie chart here:
http://www.open.imshealth.com/IMSinclude/images/r6a.gif
?Claritin rapidly became the top-selling systemic antihistamine in the
US. According to IMS data, Claritin, Allegra and Zyrtec had combined
US sales of over $3.3 billion in the 12 months to September 2002. By
comparison, Benadryl, the OTC leader with over 40% of the market, had
sales of less than $55 million in the same period, according to IMS
data.?
?In 2002, its clients spent approximately $1.3 billion on non-sedating
antihistamines, including over $600 million on Claritin.?
IMS Health
http://www.open.imshealth.com/IMSinclude/i_article_20021218.asp
http://www.imshealth.com/web/content/0,3148,64576068_63872702_70261006_70324491,00.html
===========================
Second-Generation Antihistaminas
http://www.pec.ha.osd.mil/Updates/0402web/Mar_04_Update_Page_4.htm
?The newer second-generation antihistamines do not contain
anticholinergics and so do not usually cause drowsiness to the extent
that the first generation antihistamines do. They are then sometimes
referred to collectively as nonsedating antihistamines.?
?The second-generation agents include the following:
Loratadine (Claritin)
Claritin is available over the counter and is approved for children
age two and over.
Desloratadine (Clarinex) is similar to Claritin but significantly more
potent and longer lasting. It is available only by prescription.
Cetirizine (Zyrtec)
Zyrtec is approved for both indoor and outdoor allergies. It is the
only antihistamine to date approved for infants as young as six
months.
Fexofenadine (Allegra).
Acrivastine (Semprex).?
Http://adam.about.com/reports/000077_9.htm
===========================
?The allergic rhinitis market ($10.6 billion) is largely made up of
second-generation antihistamines (67%, $6.6 billion), such as Allegra,
Zyrtec, and Clarinex, and intranasal corticosteroids (28%, $2.7
billion), such as Flonase. IMS audits indicate that the US is the
largest market for respiratory products, with sales of $16.0 billion,
representing 63% of worldwide sales.?
Datamonitor Report
Published: Apr-05
http://www.leaddiscovery.co.uk/reports/dmhc2068_rsm.pdf
===========================
The overall oral antihistamine market in 2004 was approximately $3 billion.
Elite Pharmaceuticals, Inc.
Sept. 12, 2006
http://biz.yahoo.com/bw/060912/20060912005933.html?.v=1
===========================
According to a Business Communications Company, Inc. research report,
The U.S. Market for Prescription Allergy Treatment and Management, the
total, U.S. prescription allergy treatment and management market in
2001 generated revenues of $6.45 billion.
?In 2006, this market is forecast to reach $9.6 billion, rising at an
average annual growth rate (AAGR) of 8.3%. ?
?The United States prescription allergy treatment and management
market is divided into four main categories:
antihistamines and combinations
sympathomimetics, decongestants, and combinations
corticosteroids
mast cell stabilizers?
?Growth was sustained by the antihistamines and combinations segment,
mainly from strong sales of Claritin, Allegra, and Zrytec nonsedating
antihistamines.?
The antihistamines and combinations segment will reach over $4 billion in 2006.
----------------------------------------------------------
U.S. Prescription Allergy Products Revenues by Product Type
at U.S. Manufacturers Sales Levels, through 2006
($ Billions)
----------------------------------------------------------
2001 2006
Antihistamines and combinations 2.90 4.01
Sympathomimetics, decongestants
and combinations 0.93 1.09
Corticosteroids 2.28 3.98
Mast cell stabilizers 0.34 0.52
Total 6.45 9.60
----------------------------------------------------------
Bcc Research
The U.S. Market for Prescription Allergy Treatment and Management
Published June 2002
http://www.bccresearch.com/editors/RB-156.html
===========================
Net sales for the years ended December 31, 2005, 2004 and 2003 were as
follows: (Dollars in millions)
2005 2004 2003
CLARINEX/ AERIUS 646 692 694
CLARITIN Rx(a) 371 321 328
?Global net sales of CLARINEX (marketed as AERIUS in many countries
outside the U.S.), for the treatment of seasonal outdoor allergies and
year-round indoor allergies, decreased $46 million, or 7 percent,
versus 2004. Sales in the U.S. decreased $95 million or 23 percent
versus 2004 due to reduced market share in a declining market. In
September 2005, generic Allegra (fexofenadine) was introduced to the
U.S., which will continue to negatively affect the antihistamine
market including CLARINEX. Sales outside the U.S. increased $49
million or 18 percent to $321 million in 2005 due primarily to market
share gains. Global net sales of CLARINEX were $692 million in 2004,
essentially flat versus 2003. Sales outside the U.S. increased 39
percent to $272 million in 2004 due to market share gains and
continued conversion from prescription CLARITIN. U.S. sales decreased
16 percent to $420 million in 2004 due to the continued contraction in
the U.S. prescription antihistamine market following the launch of OTC
CLARITIN and other branded and non-branded non-sedating antihistamines
coupled with market share declines.?
Form 10-K for SCHERING PLOUGH CORP
28-Feb-2006
Annual Report
http://biz.yahoo.com/e/060228/sgp10-k.html
===========================
UCB confirms that Zyrtec is the number one most prescribed branded
antihistamine in the US in new prescriptions.
?The US in-market sales of Zyrtec have reached $1,035 million during
the past 9 months ending September 30th, 2005 showing a 10% increase
against the same period in 2004, while the antihistamine market
decreased by 5%.?
?The worldwide sales of Xyzal increased by 26% during the first three
quarters 2005 versus the same period in 2004, confirming its further
market penetration. IMS market share for Xyzal in Europe reached 14%
compared to 12% a year earlier.?
Medical News Today: 26 Oct 2005
http://www.medicalnewstoday.com/medicalnews.php?newsid=32525
===========================
?The cough, cold, allergy, and asthma market is likely to remain the
leading segment in the Rx-to-OTC switched markets. This market will
generate $4.4 billion in sales in 2005, reflecting an average annual
growth rate of 27.8% through the forecast period. This intense growth
is expected to be due to the switching of the leading nonsedating
antihistamines, Claritin and Allegra. With the increasing interest in
self-medication, this market is expected to generate a continued
increase in sales.?
VRG Technologies, Inc.
http://www.vrgtech.com/analysis/rx-to-otc.html
==========================
?In 2004 the OTC cold, flu and allergy remedies market reached an
estimated $2.8 billion in sales, increasing by 5.4% at constant prices
from 1999-2004. This sharp increase is mainly due to the switch of
Schering-Plough?s Claritin to OTC status, after the company?s patent
on loratadine expired. Claritin sold over $290 million in both tablet
and liquid forms in 2003, and dropped slightly to $271.7 million in
2004. Wyeth?s loratadine tablet product, Alavert, sold nearly $59
million in its first year, 2003, and gained slightly in 2004 with
sales of $59.3 million. The combination of these two high-selling
products and the resilience of competing products are the primary
reasons for the sharp increase.?
Research and Markets
http://www.researchandmarkets.com/reportinfo.asp?cat_id=302&report_id=339095&p=1
Pharmalicensing.com
http://pharmalicensing.com/intelligence/reportsearching.php?action=toc&productID=1207023
===========================
Search terms:
non-sedating antihistamines
antihistamine market billion OR million
Singulair sales
Cough cold medicine OR medications OTC market billion
Over the counter cold cough billion 2000..2006
I hope the information provided is helpful!
Best regards,
Bobbie7 |
,
0 Comments
)
